TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 YearsGlobeNewsWire · 18 hr ago
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual MeetingGlobeNewsWire · Oct 13, 2026
Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)?Zacks Investment Research · Sep 28, 2026
Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026GuruFocus · Aug 31, 2026
Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual MeetingGlobeNewsWire · Aug 4, 2026
Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)?Zacks Investment Research · Jul 27, 2026The Invesco Dorsey Wright Healthcare Momentum ETF (PTH) is structured to mirror the performance of the Dorsey Wright Healthcare Technical Leaders Index. This exchange-traded fund typically allocates a minimum of 90% of its total assets to the equities found within this benchmark index. The Index itself is specifically engineered to identify healthcare companies that demonstrate strong "relative strength," which indicates significant momentum.